NCT06806579 Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma
| NCT ID | NCT06806579 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Hepatocellular Carcinoma (HCC) |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2022-12-21 |
| Primary Completion | 2030-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,000 participants in total. It began in 2022-12-21 with a primary completion date of 2030-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
\- Background Hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third leading cause of cancer-related death. In most cases (about 80%), HCC develops in a cirrhotic liver - a condition where the liver has been damaged over time, leading to scarring. This makes treatment more challenging. This study will gather and analyze data from patients treated in real-world settings to: 1. Understand the effectiveness and safety of new treatment combinations (e.g., atezolizumab-bevacizumab and durvalumab-tremelimumab). Identify the best treatment sequences for patients with advanced liver cancer. 2. Discover clinical and laboratory markers that predict treatment responses, helping personalize care and optimize outcomes. By addressing these questions, this study will provide valuable information to healthcare providers and guide future treatment decisions for patients with liver cancer.
Eligibility Criteria
Inclusion Criteria: * Hepatocellular carcinoma not amenable to locoregional procedures * Candidate to frontline systemic treatment with atezolizumab-bevacizumab or other immunotherapies Exclusion Criteria: * Concurrent treatment with other antineoplastic agents * Other active neoplasia
Contact & Investigator
Francesco Tovoli, MD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06806579 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Hepatocellular Carcinoma (HCC). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06806579 currently recruiting?
Yes, NCT06806579 is actively recruiting participants. Contact the research team at francesco.tovoli@unibo.it for enrollment information.
Where is the NCT06806579 trial being conducted?
This trial is being conducted at Torrette, Italy, Castellana Grotte, Italy, Bologna, Italy, Bologna, Italy and 11 additional locations.
Who is sponsoring the NCT06806579 clinical trial?
NCT06806579 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Francesco Tovoli, MD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 1,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.